The Red Sox announced some very welcome news on lefty David Price, who was being evaluated for a worrying elbow injury. As Rob Bradford of WEEI.com was among those to report on Twitter, manager John Farrell says that Price is not expected to require surgery or other invasive treatments. Instead, he will be shut down for seven to ten days of treatment before being reevaluated.

It’s not immediately clear how soon Price can be expected back on the mound. The injury has been diagnosed as a strain, per Jason Mastrodonato of the Boston Herald (via Twitter), which presumably could have a wide variance in recovery process and timing. Clearly, though, the news comes as a relief to a Boston organization that has much at stake in Price’s left arm — this season and beyond.

Alarm bells rang yesterday when the Sox told reporters they were sending Price to be examined by elbow experts Dr. James Andrews and Dr. Neal ElAttrache. That decision showed that the team had real concern, and raised the specter of a season-ending surgery. Those two physicians, after all, are among the foremost practitioners of the Tommy John procedure. While a visit to their offices often precedes a TJ procedure, though, that’s not always the case.

In Price’s situation, it seems, other treatment outcomes were also seen as being on the table. Ferrell noted that the veteran southpaw won’t need an injection, which perhaps would have represented an alternative. As it turns out, the news represents a best-case scenario.

Unfortunately, even with that good news, it seems as if Price may fall behind a bit. Unless, perhaps, he’s cleared for a full resumption of this throwing program at the earliest opportunity, Price may need to spend at least a bit of time on the DL to start the season. That wouldn’t be particularly problematic were it not for the fact that Boston is facing similar timing questions already with pitchers such as Steven Wright and Drew Pomeranz, though perhaps a fill-in or even an outside addition could help bridge the gap if the need arises.

View Comments (65)